ClinicalTrials.gg
CompletedNCT04349098CoronavirusUpdated Jan 20, 2023Results posted

Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection

A Phase 2 interventional study of Selinexor and Placebo in Coronavirus Infection, sponsored by Karyopharm Therapeutics Inc. Completed at 33 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-20.

Primary conditionCOVID-19Registry: Coronavirus InfectionsReclassifiedWhy we changed it
Registry
Coronavirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's title name COVID-19, a narrower term within Coronavirus Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
498th of 1,321
190 · median 91
Started
2020
with 817 others
Phase 2
349 of 1,859
14 open now
Registered
154th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 498th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 154th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the activity of low dose oral selinexor (KPT-330) and to evaluate the clinical recovery, the viral load, length of hospitalization and the rate of morbidity and mortality in participants with severe COVID-19 compared to placebo. The study had 2 arms and evaluated selinexor 20 mg + standard of care (SoC) and placebo + SoC. As the treatment for COVID-19 is rapidly evolving, the SoC varied over time and across regions of the world.

03

Conditions studied

  • Coronavirus Infection

Browse trials for

Keywords

  • COVID-19
  • SARS-CoV-2
04

In context

COVID-19 Reclassified

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

This study's enrollment of 190 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Karyopharm Therapeutics Inc is the lead sponsor of 37 studies on the registry; 4 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed laboratory diagnosis of SARS-CoV2 by standard FDA-approved reverse transcription polymerase chain reaction (RT-PCR) assay or equivalent FDA-approved testing (local labs).
  • Currently hospitalized.
  • provided as above (it is recommended that participants are dosed with study drug within 12 hours of consent).
  • Has symptoms of severe COVID-19 as demonstrated by:

    • At least one of the following: fever, cough, sore throat, malaise, headache, muscle pain, shortness of breath at rest or with exertion, confusion, or symptoms of severe lower respiratory symptoms including dyspnea at rest or respiratory distress.
    • Clinical signs indicative of lower respiratory infection with COVID-19, with at least one of the following: SaO2 \<92% on room air in last 12 hours or requires > 4 liters per minute (LPM) oxygen by nasal canula, non-rebreather/Ventimask or high flow nasal canula in order maintain SaO2 ≥92%, PaO2/FiO2 \<300 millimeter per mercury (mm/hg).
  • Elevated C-reactive protein (CRP) > 2 x (ULN).
  • Concurrent anti-viral and/or anti-inflammatory agents (e.g., biologics, hydroxychloroquine) are permitted. If in the physician's judgment, it is in the best interest of the participant to use anti-viral or anti-inflammatory treatments, these treatments are to be documented in the participant's chart and entered in the electronic case report form.
  • Female participants of must have a negative serum pregnancy test at Screening. Female participants of childbearing potential and fertile male participants must use highly effective methods of throughout the study and for 3 months following the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Evidence of critical COVID-19 based on:

    • Respiratory failure (defined by endotracheal intubation and mechanical ventilation, oxygen delivered by noninvasive positive pressure ventilation, or clinical diagnosis of respiratory failure in setting of resource limitations)
    • Septic shock (defined by Systolic blood pressure [BP] \< 90 mm Hg, or Diastolic BP \< 60 mm Hg)
    • Multiple organ dysfunction/failure
  • In the opinion of the investigator, unlikely to survive for at least 48 hours from screening or anticipate mechanical ventilation within 48 hours.
  • Inadequate hematologic parameters as indicated by the following labs:

    • Participants with severe neutropenia (ANC \<1000 x 10\^9/L) or
    • Thrombocytopenia (e.g., \<100,000 per microliter of blood)
  • Inadequate renal and liver function as indicated by the following labs:

    • (CrCL) \<20 mL/min using the formula of Cockcroft and Gault
    • (AST) or alanine transaminase (ALT) > 5 x
  • Hyponatremia defined as sodium \< 135 milliequivalents per liter (mEq/L).
  • Unable to take oral medication when is obtained.
  • Participants with a legal guardian or who are incarcerated.
  • Treatment with strong inhibitors or inducers.
  • Pregnant and breastfeeding women.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    Selinexor 20 mg

    Participants will receive 20 milligram (mg) of selinexor oral tablet on Days 1, 3, and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).

    Drug: Selinexor

  • Placebo comparator
    Placebo

    Participants will receive 20 mg of placebo matched to selinexor oral tablet on Days 1, 3, and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).

    Other: Placebo

Interventions

  • Participants will receive 20 mg of selinexor.

    Also known as: KPT-330, XPOVIO

  • OtherPlacebo

    Participants will receive 20 mg of placebo matched to selinexor.

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With At-least a 2-Point Improvement in Ordinal Scale

    Ordinal Scale 2-Point improvement was defined as percentage of participants with at least a 2-points improvement (increase from baseline) by Day 14. Baseline score was defined as the last score measured before first dosing. The 8-point ordinal scale ranges from 1 to 8: where 1= death, 2= hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3= hospitalized, on non-invasive ventilation or high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus disease 2019 \[COVID-19\] related or otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7= not hospitalized, limitation on activities and/or requiring home oxygen; 8= not hospitalized, no limitations on activities.

    Time frame: Baseline up to Day 14

Secondary outcomes

  1. Percentage of Participants With at Least a 2-Point Improvement in the Ordinal Scale up to Day 7

    Ordinal Scale 2-points improvement was defined as percentage of participants with at least a 2-points improvement (increase from baseline) by Day 7. Baseline score was defined as the last score measured before first dosing. The 8-point ordinal scale ranges from 1 to 8: where, 1= death, 2= hospitalized, on invasive mechanical ventilation or ECMO; 3= hospitalized, on non-invasive ventilation or high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7= not hospitalized, limitation on activities and/or requiring home oxygen; 8= not hospitalized, no limitations on activities.

    Time frame: Baseline up to Day 7

  2. Percentage of Participants With at Least a 1-Point Improvement in the Ordinal Scale

    Ordinal Scale 1-point improvement was defined as percentage of participants with at least 1-point improvement (increase from baseline) by Day 7 and 14. Baseline score was defined as the last score measured before first dosing. The 8-point ordinal scale ranges from 1 to 8: where 1= death, 2= hospitalized, on invasive mechanical ventilation or ECMO; 3= hospitalized, on non-invasive ventilation or high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7= not hospitalized, limitation on activities and/or requiring home oxygen; 8= not hospitalized, no limitations on activities.

    Time frame: Baseline up to Day 7 and 14

  3. Time to Clinical Improvement of 2-points Using Ordinal Scale (TTCI-2)

    TTCI-2 was defined as the time from randomization to an improvement of 2-points using 8-points Ordinal Scale. The 8-point ordinal scale ranges from 1 to 8: where 1= death, 2= hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3= hospitalized, on non-invasive ventilation or high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus disease 2019 \[COVID-19\] related or otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7= not hospitalized, limitation on activities and/or requiring home oxygen; 8= not hospitalized, no limitations on activities.

    Time frame: Baseline up to Day 28

  4. Overall Death Rate

    Overall death rate was defined as the percentage of participants who died on or before Day 28.

    Time frame: Baseline up to Day 28

  5. Rate of Mechanical Ventilation (RMV)

    The rate of RMV was defined as the percentage of participants who ever used invasive mechanical ventilation or ECMO during the hospital stay.

    Time frame: Baseline up to Day 28

  6. Rate of Intensive Care Unit (ICU) Admission

    The rate of ICU admission was defined as the percentage of participants with ICU admissions.

    Time frame: Baseline up to Day 28

  7. Length of Hospitalization

    Length of hospitalization (days) was defined as (first hospital discharge date - date of randomization + 1).

    Time frame: Baseline up to Day 67

  8. Change From Baseline in C-reactive Protein (CRP) Levels

    The anti-inflammatory and immune effects of selinexor were assessed by CRP levels. Baseline was defined as the most recent non-missing measurement prior to the first administration of study treatment. Change from Baseline at the indicated time points was calculated as the value at the indicated time points minus the value at Baseline.

    Time frame: Baseline, Day 3, 5, 8, 12, 15, 19, 22 and 26

  9. Change From Baseline in Ferritin Levels

    The anti-inflammatory and immune effects of selinexor were assessed by ferritin levels. Baseline was defined as the most recent non-missing measurement prior to the first administration of study treatment. Change from Baseline at the indicated time points was calculated as the value at the indicated time points minus the value at Baseline.

    Time frame: Baseline, Day 3, 5, 8, 12, 15, 19, 22 and 26

  10. Change From Baseline in Lactate Dehydrogenase (LDH) Levels

    The anti-inflammatory and immune effects of selinexor were assessed by LDH levels. Baseline was defined as the most recent non-missing measurement prior to the first administration of study treatment. Change from Baseline at the indicated time points was calculated as the value at the indicated time points minus the value at Baseline.

    Time frame: Baseline, Day 3, 5, 8, 12, 15, 19, 22 and 26

  11. Changes From Baseline in Blood Plasma Cytokines Levels-Interleukin-6 (IL-6)

    The anti-inflammatory and immune effects of selinexor were assessed by blood plasma cytokines like IL-6. Baseline was defined as the most recent non-missing measurement prior to the first administration of study treatment. Change from Baseline at the indicated time points was calculated as the value at the indicated time points minus the value at Baseline.

    Time frame: Baseline, Day 3, 5, 8, 12, 15, 22 and 26

  12. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    Adverse events are defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. Serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both Serious and non-serious TEAEs.

    Time frame: From start of study drug administration up to Day 58

08

Results

Posted Nov 1, 2021

Participant flow

This study was conducted at 20 sites in the United States of America,1 site in Austria, 3 sites in France and Israel, 2 sites in Spain, and 4 sites in the United Kingdom from 17 Apr 2020 to 05 Oct 2020.

Participant flow — Overall Study
MilestoneSelinexor 20 mgPlacebo
Started10387
Treated10286
Completed6561
Not completed3826
Withdrew: Death168
Withdrew: Lost to follow-up118
Withdrew: Withdrawal by subject85
Withdrew: Other35

Outcome measures

PrimaryPercentage of Participants With At-least a 2-Point Improvement in Ordinal Scale

Ordinal Scale 2-Point improvement was defined as percentage of participants with at least a 2-points improvement (increase from baseline) by Day 14. Baseline score was defined as the last score measured before first dosing. The 8-point ordinal scale ranges from 1 to 8: where 1= death, 2= hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3= hospitalized, on non-invasive ventilation or high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus disease 2019 \[COVID-19\] related or otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7= not hospitalized, limitation on activities and/or requiring home oxygen; 8= not hospitalized, no limitations on activities.

Time frame:
Baseline up to Day 14
Reported as:
Number · Percentage of participants
Percentage of Participants With At-least a 2-Point Improvement in Ordinal Scale
Percentage of participantsSelinexor 20 mgPlacebo
Percentage of Participants With At-least a 2-Point Improvement in Ordinal Scale60.6 (47.8 to 72.4)60.8 (46.1 to 74.2)
Statistical analysis
  • Selinexor 20 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.6750 · Odds ratio (or): 0.84 · 95% CI 0.39 to 1.79
SecondaryPercentage of Participants With at Least a 2-Point Improvement in the Ordinal Scale up to Day 7

Ordinal Scale 2-points improvement was defined as percentage of participants with at least a 2-points improvement (increase from baseline) by Day 7. Baseline score was defined as the last score measured before first dosing. The 8-point ordinal scale ranges from 1 to 8: where, 1= death, 2= hospitalized, on invasive mechanical ventilation or ECMO; 3= hospitalized, on non-invasive ventilation or high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7= not hospitalized, limitation on activities and/or requiring home oxygen; 8= not hospitalized, no limitations on activities.

Time frame:
Baseline up to Day 7
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least a 2-Point Improvement in the Ordinal Scale up to Day 7
Percentage of participantsSelinexor 20 mgPlacebo
Percentage of Participants With at Least a 2-Point Improvement in the Ordinal Scale up to Day 730.1 (21.5 to 39.9)32.2 (22.6 to 43.1)
SecondaryPercentage of Participants With at Least a 1-Point Improvement in the Ordinal Scale

Ordinal Scale 1-point improvement was defined as percentage of participants with at least 1-point improvement (increase from baseline) by Day 7 and 14. Baseline score was defined as the last score measured before first dosing. The 8-point ordinal scale ranges from 1 to 8: where 1= death, 2= hospitalized, on invasive mechanical ventilation or ECMO; 3= hospitalized, on non-invasive ventilation or high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7= not hospitalized, limitation on activities and/or requiring home oxygen; 8= not hospitalized, no limitations on activities.

Time frame:
Baseline up to Day 7 and 14
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least a 1-Point Improvement in the Ordinal Scale
Percentage of participantsSelinexor 20 mgPlacebo
Day 751.5 (41.4 to 61.4)50.6 (39.6 to 61.5)
Day 1472.8 (63.2 to 81.1)72.4 (61.8 to 81.5)
SecondaryTime to Clinical Improvement of 2-points Using Ordinal Scale (TTCI-2)

TTCI-2 was defined as the time from randomization to an improvement of 2-points using 8-points Ordinal Scale. The 8-point ordinal scale ranges from 1 to 8: where 1= death, 2= hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3= hospitalized, on non-invasive ventilation or high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus disease 2019 \[COVID-19\] related or otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7= not hospitalized, limitation on activities and/or requiring home oxygen; 8= not hospitalized, no limitations on activities.

Time frame:
Baseline up to Day 28
Reported as:
Median · Days
Time to Clinical Improvement of 2-points Using Ordinal Scale (TTCI-2)
DaysSelinexor 20 mgPlacebo
Time to Clinical Improvement of 2-points Using Ordinal Scale (TTCI-2)10.0 (8.0 to 14.0)10.0 (8.0 to 14.0)
SecondaryOverall Death Rate

Overall death rate was defined as the percentage of participants who died on or before Day 28.

Time frame:
Baseline up to Day 28
Reported as:
Number · Percentage of participants
Overall Death Rate
Percentage of participantsSelinexor 20 mgPlacebo
Overall Death Rate15.2 (7.5 to 26.1)3.9 (0.5 to 13.5)
SecondaryRate of Mechanical Ventilation (RMV)

The rate of RMV was defined as the percentage of participants who ever used invasive mechanical ventilation or ECMO during the hospital stay.

Time frame:
Baseline up to Day 28
Reported as:
Number · Percentage of participants
Rate of Mechanical Ventilation (RMV)
Percentage of participantsSelinexor 20 mgPlacebo
Rate of Mechanical Ventilation (RMV)13.6 (6.4 to 24.3)11.8 (4.4 to 23.9)
SecondaryRate of Intensive Care Unit (ICU) Admission

The rate of ICU admission was defined as the percentage of participants with ICU admissions.

Time frame:
Baseline up to Day 28
Reported as:
Number · Percentage of participants
Rate of Intensive Care Unit (ICU) Admission
Percentage of participantsSelinexor 20 mgPlacebo
Rate of Intensive Care Unit (ICU) Admission48.5 (36.0 to 61.1)41.2 (27.6 to 55.8)
SecondaryLength of Hospitalization

Length of hospitalization (days) was defined as (first hospital discharge date - date of randomization + 1).

Time frame:
Baseline up to Day 67
Reported as:
Median · Days
Length of Hospitalization
DaysSelinexor 20 mgPlacebo
Length of Hospitalization9.0 (3 to 39)9.0 (3 to 67)
SecondaryChange From Baseline in C-reactive Protein (CRP) Levels

The anti-inflammatory and immune effects of selinexor were assessed by CRP levels. Baseline was defined as the most recent non-missing measurement prior to the first administration of study treatment. Change from Baseline at the indicated time points was calculated as the value at the indicated time points minus the value at Baseline.

Time frame:
Baseline, Day 3, 5, 8, 12, 15, 19, 22 and 26
Reported as:
Mean · milligram per liter (mg/L)
Change From Baseline in C-reactive Protein (CRP) Levels
milligram per liter (mg/L)Selinexor 20 mgPlacebo
Change at Day 3-47.9660 ± 99.06082-42.9658 ± 89.09341
Change at Day 5-74.4735 ± 114.52388-68.6191 ± 108.19671
Change at Day 8-83.3460 ± 93.83500-74.4669 ± 117.66505
Change at Day 12-86.9158 ± 123.54705-93.2744 ± 131.56709
Change at Day 15-87.9800 ± 121.19999-98.7940 ± 87.65276
Change at Day 19-66.2143 ± 86.55049-124.3233 ± 102.04161
Change at Day 22-90.7100 ± 149.25579-47.5620 ± 171.49171
Change at Day 26-37.2800 ± 141.41390-129.5020 ± 46.26178
SecondaryChange From Baseline in Ferritin Levels

The anti-inflammatory and immune effects of selinexor were assessed by ferritin levels. Baseline was defined as the most recent non-missing measurement prior to the first administration of study treatment. Change from Baseline at the indicated time points was calculated as the value at the indicated time points minus the value at Baseline.

Time frame:
Baseline, Day 3, 5, 8, 12, 15, 19, 22 and 26
Reported as:
Mean · microgram/liter (mcg/L)
Change From Baseline in Ferritin Levels
microgram/liter (mcg/L)Selinexor 20 mgPlacebo
Change at Day 380.8415 ± 759.10075-61.9843 ± 542.09460
Change at Day 5-25.7000 ± 856.16619-155.3111 ± 773.76777
Change at Day 8226.6113 ± 1673.46162-292.2462 ± 738.07874
Change at Day 12193.5793 ± 1203.33385-352.5280 ± 741.13673
Change at Day 15204.3900 ± 557.29217-356.8429 ± 476.04151
Change at Day 19-15.9333 ± 462.40358-231.2374 ± 599.98919
Change at Day 22-103.9900 ± 636.89555-102.0000 ± 417.51247
Change at Day 26-150.1167 ± 535.94141-25.7500 ± 231.43232
SecondaryChange From Baseline in Lactate Dehydrogenase (LDH) Levels

The anti-inflammatory and immune effects of selinexor were assessed by LDH levels. Baseline was defined as the most recent non-missing measurement prior to the first administration of study treatment. Change from Baseline at the indicated time points was calculated as the value at the indicated time points minus the value at Baseline.

Time frame:
Baseline, Day 3, 5, 8, 12, 15, 19, 22 and 26
Reported as:
Mean · units/liter (U/L)
Change From Baseline in Lactate Dehydrogenase (LDH) Levels
units/liter (U/L)Selinexor 20 mgPlacebo
Change at Day 3-13.86 ± 148.231-11.86 ± 151.630
Change at Day 5-49.12 ± 175.72231.85 ± 326.281
Change at Day 8-75.85 ± 264.840-10.93 ± 166.876
Change at Day 12-107.39 ± 198.092-16.84 ± 232.605
Change at Day 15-71.82 ± 193.543-51.50 ± 148.063
Change at Day 19-96.38 ± 200.164-74.14 ± 114.271
Change at Day 22-129.70 ± 177.454-75.40 ± 43.569
Change at Day 26-169.50 ± 213.4814.50 ± 130.733
SecondaryChanges From Baseline in Blood Plasma Cytokines Levels-Interleukin-6 (IL-6)

The anti-inflammatory and immune effects of selinexor were assessed by blood plasma cytokines like IL-6. Baseline was defined as the most recent non-missing measurement prior to the first administration of study treatment. Change from Baseline at the indicated time points was calculated as the value at the indicated time points minus the value at Baseline.

Time frame:
Baseline, Day 3, 5, 8, 12, 15, 22 and 26
Reported as:
Mean · nanograms/milliliter (ng/mL)
Changes From Baseline in Blood Plasma Cytokines Levels-Interleukin-6 (IL-6)
nanograms/milliliter (ng/mL)Selinexor 20 mgPlacebo
Change at Day 3-19.931 ± 51.20722.046 ± 49.0258
Change at Day 5-10.786 ± 102.9160-77.509 ± 408.0085
Change at Day 8-13.909 ± 161.6803183.728 ± 662.7908
Change at Day 12276.289 ± 1541.3692223.637 ± 715.5904
Change at Day 15-34.850 ± 28.6357207.625 ± 408.5783
Change at Day 22-8.600 ± 11.8072—
Change at Day 26-23.400—
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

Adverse events are defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. Serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both Serious and non-serious TEAEs.

Time frame:
From start of study drug administration up to Day 58
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsSelinexor 20 mgPlacebo
Participants with TEAEs7549
Participants with Serious TEAEs2314

Adverse events

Collected over From start of study drug administration up to Day 58. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selinexor 20 mg16/102 (15.7%)23/102 (22.5%)69/102 (67.6%)
Placebo8/86 (9.3%)14/86 (16.3%)45/86 (52.3%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventSelinexor 20 mgPlacebo
Respiratory failureRespiratory, thoracic and mediastinal disorders6/1022/86
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/1022/86
Myocardial infarctionCardiac disorders0/1022/86
Multiple organ dysfunction syndromeGeneral disorders0/1022/86
COVID-19Infections and infestations0/1022/86
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/1022/86
Cardiac arrestCardiac disorders2/1020/86
Acute kidney injuryRenal and urinary disorders2/1021/86
PneumothoraxRespiratory, thoracic and mediastinal disorders2/1020/86
Atrial fibrillationCardiac disorders1/1021/86
Most frequent other events
Showing 10 of 16
Most frequent other events
EventSelinexor 20 mgPlacebo
HyponatraemiaMetabolism and nutrition disorders24/1025/86
ConstipationGastrointestinal disorders14/1029/86
NauseaGastrointestinal disorders13/1026/86
DiarrhoeaGastrointestinal disorders10/1024/86
AnaemiaBlood and lymphatic system disorders9/1021/86
Aspartate aminotransferase increasedInvestigations9/1027/86
Alanine aminotransferase increasedInvestigations8/1024/86
HyperglycaemiaMetabolism and nutrition disorders7/1023/86
HypoxiaRespiratory, thoracic and mediastinal disorders6/1022/86
HypoalbuminaemiaMetabolism and nutrition disorders4/1025/86

Baseline characteristics

PV 1-6 population included participants randomized into the study under protocol versions 1-6.

Age, Continuous
Age, Continuous(Years)Selinexor 20 mgPlaceboTotal
Mean56.5 ± 16.1256.5 ± 14.6456.5 ± 15.42
Sex: Female, Male
Sex: Female, Male(Participants)Selinexor 20 mgPlaceboTotal
Female433982
Male6048108
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Selinexor 20 mgPlaceboTotal
Hispanic or Latino413273
Not Hispanic or Latino5953112
Unknown or Not Reported325
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Selinexor 20 mgPlaceboTotal
American Indian or Alaska Native000
Asian6410
Native Hawaiian or Other Pacific Islander202
Black or African American232447
White443478
More than one race191433
Unknown or Not Reported91120
09

Study locations

33 sites
  • UCLA
    Los Angeles, California 90095, United States
  • Kaiser Permanente Oakland
    Oakland, California 94612, United States
  • UC Davis Health
    Sacramento, California 95817, United States
  • Kaiser Permanente Sacramento
    Sacramento, California 95825, United States
  • Kaiser Permanente San Francisco
    San Francisco, California 94115, United States
  • Miami Cancer Institute at Baptist Health
    Miami, Florida 33176, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Advocate Christ Medical Center
    Oak Lawn, Illinois 60453, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 64113, United States
  • Norton Healthcare
    Louisville, Kentucky 40202, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • Karmanos
    Detroit, Michigan 48201, United States
  • Michigan Center of Medical Research
    Farmington Hills, Michigan 48336, United States
  • Michigan Center of Medical Research
    Royal Oak, Michigan 48073, United States
  • Columbia University
    New York, New York 10032, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • Levine Cancer Institute-Atrium Health University City
    Charlotte, North Carolina 28204, United States
  • Lehigh Valley Hospital
    Allentown, Pennsylvania 18103, United States
  • Baylor Scott & White Dallas
    Dallas, Texas 75201, United States
  • MultiCare Institute for Research & Innovation (Puget Sound)
    Tacoma, Washington 98405, United States
  • Hospital Hietzing, 2. Medical department - Center for Diagnosis and Therapy of Rheumatic Diseases
    Vienna, Austria
  • CHU Bordeaux
    Bordeaux, 33076, France
  • CHU Lyon
    Lyon, 69004, France
  • CHU Nantes
    Nantes, 44093, France
  • Hadassah MC
    Jerusalem, Israel
  • Hasharon Medical Center
    Petah Tiqva, Israel
  • Sheba Medical Center
    Tel HaShomer, Israel
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Servicio de Medicina Interna, Hospital Universitario de Salamanca, Universidad de Salamanca
    Salamanca, 37007, Spain
  • Princess Royal University Hospital
    Kent, BR6 8ND, United Kingdom
  • Kings College Hospital
    London, SE5 9RS, United Kingdom
  • The Royal Marsden Hospital
    London, SW3 6JJ, United Kingdom
  • University Hospitals Plymouth NHS Trust
    Plymouth, PL6 5FP, United Kingdom
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Oct 2020, 5 months.

Results were first posted in Nov 2021, 1 year after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 5 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2020
First posted
Apr 16, 2020
StartActual
Apr 17, 2020
Primary completionActual
Oct 5, 2020
CompletionActual
Oct 5, 2020
Results first posted
Nov 1, 2021
Last update
Jan 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04349098
Responsible party
Sponsor
First posted
Apr 16, 2020
Start date
Apr 17, 2020
Primary completion
Oct 5, 2020
Completion
Oct 5, 2020
Results posted
Nov 1, 2021
Last update
Jan 20, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion